HR Execs on the Move

Novavax

www.novavax.com

 
Novavax, Inc. (Nasdaq: NVAX), a clinical-stage biopharmaceutical company, employs its cutting-edge technology to create next-generation vaccines to prevent serious infectious diseases, such as pandemic and seasonal influenza and respiratory syncytial virus (RSV). The company’s proprietary virus-like-particle (VLP) technology and single-use bioprocessing system enable rapid vaccine development and production where and when they are needed, worldwide. The company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India. Additional information about Novavax is available on the company’s website
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.novavax.com
  • 20 Firstfield Road
    Gaithersburg, MD USA 20878
  • Phone: 240.268.2000

Executives

Name Title Contact Details
Tony Handzic-Smith
Vice President, Global Supply Chain Planning and Network Strategy Profile
Talitha Hampton
Senior Director, Global Supply Chain and Strategic Sourcing Profile
Ashvin Patel
Associate Director Revenue and OTC Profile
Ali Rahman
Director, External Drug Product Manufacturing Operations at NOVAVAX Profile
Bibin Abraham
Head of HR Technology and Analytics Profile

Similar Companies

Threshold Pharmaceuticals

Threshold Pharmaceuticals, Inc. is a Redwood City, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Yumanity

Yumanity Therapeutics is transforming drug discovery for neurodegenerative diseases caused by protein misfolding. Despite the fact that an estimated 50 million people worldwide suffer from diseases affecting the brain and central nervous system, there are no approved disease-modifying therapies or cures. Yumanity is working to identify and develop new, disease-modifying therapies that address several illnesses with critical unmet medical needs, including Alzheimer`s disease, Parkinson`s disease and amyotrophic lateral sclerosis (ALS). The company`s approach concentrates on correcting the cellular pathologies driven by misfolded proteins, the altered biology or phenotypes driving these diseases. Yumanity Therapeutics was founded in December 2014 by Susan Lindquist, Ph.D., award-winning protein folding expert, and Tony Coles, M.D., a renowned biotech industry leader. The company`s proprietary platforms have already identified one potential new target for treating Parkinson`s disease, and Yumanity is actively advancing its new chemical lead series for this condition, as well as identifying additional compounds for Alzheimer`s disease and ALS. Targeting the underlying protein pathology of neurodegenerative diseases allows the company to discover therapies that may modify the root cause of these rather than only addressing their symptoms.

Manifold Bio

A next-generation protein therapeutics company pioneering an in vivo biologics design platform. By redesigning in vivo measurement to be available from day one, Manifold Bio has an advantage in solving complex biologic challenges.

Whole Biome

Whole Biome`s mission is to be the trusted brand in bringing the public improved health solutions through microbiome interventions. We are developing microbiome diagnostics and interventions using our proprietary discovery platform.

Virsys

Virsys is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.